Degenerative Disc Disease (DDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Degenerative Disc Disease (DDD) Market Outlook

Thelansis’s “Degenerative Disc Disease (DDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Degenerative disc disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Degenerative Disc Disease (DDD) Overview

Degenerative intervertebral disc disease (DDD) is an age-related condition contributing to low back pain. DDD impairs the functional capacity of intervertebral discs, rendering them incapable of bearing physiological loads. This leads to damage to the structural integrity of the discs and the formation of disc herniation, osteophytes, and vertebral micro-fractures. The precise pathogenesis of DDD and its relationship with environmental and genetic factors are poorly understood. However, disc degeneration is strongly associated with occupational activities involving heavy physical loading. Common symptoms indicating that degenerative disc disease may cause neck pain include neck pain, pain radiating to the shoulder blades or arms, numbness, tingling, and occasional difficulties with hand dexterity. Occupational risk factors, such as prolonged abnormal postures, bending, vibration, twisting, sitting, and heavy lifting, are suspected to be linked to disc degeneration and herniation. Degenerative disc disease can also result in back or leg pain, functional issues such as tingling or numbness in the legs or buttocks, or difficulty walking. The vitamin D receptor (VDR), a nuclear steroid hormone receptor family member, is believed to play a crucial role in normal bone mineralization and remodeling. Various disorders, including osteoporosis, osteoarthritis, and DDD, have been associated with gene polymorphisms of the VDR. Disc degeneration is classified with standard criteria such as the Thompson Grading Scale. The scale has five levels, ranging from grade 1 (not degenerated) to grade 5 (severely degenerated). In 2001, a five-level grading scale, the Pfirrmann classification, was proposed for evaluating disc degeneration based on T2-weighted images. According to this classification, grade I discs have a uniformly high signal in the nucleus on T2-weighted images, grade II discs show a central horizontal line of low signal intensity on sagittal images, grade III discs display high intensity in the central part of the nucleus with lower intensity in the peripheral regions, grade IV discs exhibit low signal intensity centrally and blurred distinction between the nucleus and annulus, and grade V discs show homogeneous low signal with no differentiation between the nucleus and annulus.

• Approximately 40% of adults over 40 have at least one degenerated vertebral disc; by the age of 80, this percentage increases to 80%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: